GlassScriptPhysician profile
Leslie A Ware
NPI 1245236249
$6,031.39
in general payments reported to CMS, 2019-2025
17 companies · $805 in 2025
The $805 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $1,025 · 2023: $1,702 · 2024: $1,786 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,333.41 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,835.19 | 2021-2025 | Descovy, Biktarvy |
| Abbvie INC. | $352.61 | 2022-2024 | |
| Janssen Biotech, INC. | $346.88 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $288.86 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Biohaven Pharmaceuticals, INC. | $171.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.23 | 2022 | |
| Pfizer INC. | $138.27 | 2021-2025 | |
| Exact Sciences Corporation | $82.25 | 2023-2024 | Cologuard Collection Kit |
| Janssen Products, LP | $80.80 | 2023 | Symtuza |
| Revance Therapeutics, INC. | $79.54 | 2024 | Daxi |
| Novo Nordisk INC | $59.53 | 2022-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $32.98 | 2021 | |
| Amarin Pharma, INC. | $23.29 | 2021 | |
| Hologic Sales and Service, LLC | $23.20 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.91 | 2021 | |
| Corcept Therapeutics | $13.00 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.